The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public–Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1. | Zendy

Bruno François | Zendy; Jean Chastre | Zendy; P. Eggiman | Zendy; PierreFrançois Laterre | Zendy; Antoní Torres | Zendy; Miguel Sánchez | Zendy; Mark T. Esser | Zendy; Brian Bishop | Zendy; Marc J. M. Bonten | Zendy; Herman Goosens | Zendy; Hasan S. Jafri | Zendy

Open Access

The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public–Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia: Table 1.

Author(s) -

Bruno François,

Jean Chastre,

P. Eggiman,

PierreFrançois Laterre,

Antoní Torres,

Miguel Sánchez,

Mark T. Esser,

Brian Bishop,

Marc J. M. Bonten,

Herman Goosens,

Hasan S. Jafri

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw245

Subject(s) - medicine , general partnership , pneumonia , clinical trial , intensive care medicine , business , finance

The Innovative Medicines Initiative-funded COMBACTE consortium fosters academic-industry partnership in pioneering studies to combat serious bacterial infections. We describe how this partnership is advancing the development of 2 monoclonal antibodies, MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research